AbCellera director buys 53,613 shares at $10.64

AbCellera Biologics Inc. director Michael R. Hayden reported an indirect open-market purchase of 53,613 Common Shares of ABCL on 2026-08-24 at a weighted-average price of $10.64 per share, from multiple trades between $10.49 and $10.70.

Rhea-AI Filing Summary

AbCellera Biologics Inc. director Michael R. Hayden reported an indirect open-market purchase of 53,613 Common Shares of ABCL on 2026-08-24 at a weighted-average price of $10.64 per share, from multiple trades between $10.49 and $10.70. These shares, totaling 1,373,397 after the purchase, are held by Genworks 2 Consulting, Inc., over which his spouse has sole voting and investment power. Hayden disclaims beneficial ownership except for any indirect pecuniary interest. A separate indirect holding of 118,245 Common Shares is reported as held by his spouse.

Insider Trade Summary

Net Buyer: 53,613 shares

Net Buy 2 txns

Insider Hayden Michael R

Role Director

Bought 53,613 shs ($570K)

Type	Security	Shares	Price	Value
Purchase	Common Shares F1, F2	53,613	$10.64	$570K
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 1,373,397 shares (Indirect, See footnote); Common Shares — 118,245 shares (Indirect, By spouse)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.49 to $10.70. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
2. F2. These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

Key Figures

Shares purchased: 53,613 Common Shares Weighted-average purchase price: $10.64 per share Purchase price range: $10.49–$10.70 per share +2 more

5 metrics

Shares purchased 53,613 Common Shares Indirect purchase on 2026-08-24

Weighted-average purchase price $10.64 per share Price for 53,613 Common Shares acquired on 2026-08-24

Purchase price range $10.49–$10.70 per share Range of prices for the multiple transactions comprising the 53,613-share purchase

Indirect holdings via Genworks 2 after transaction 1,373,397 Common Shares Total Common Shares held indirectly after the 53,613-share purchase

Indirect holdings by spouse 118,245 Common Shares Separate indirect holding reported as held by spouse

Key Terms

weighted-average price, beneficial ownership, indirect pecuniary interest, voting and investment power

4 terms

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

beneficial ownership financial

"The reporting person disclaims beneficial ownership of such securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

indirect pecuniary interest financial

"except to the extent of his indirect pecuniary interest, if any, therein"

voting and investment power financial

"spouse has sole voting and investment power with respect to the shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did ABCL director Michael R. Hayden report on this Form 4?

He reported an indirect purchase of 53,613 AbCellera (ABCL) Common Shares on 2026-08-24 at a weighted-average price of $10.64 per share, from trades executed between $10.49 and $10.70.

At what prices were Michael R. Hayden’s ABCL shares acquired?

The reported $10.64 price is a weighted-average. The 53,613 AbCellera (ABCL) shares were acquired in multiple transactions at prices ranging from $10.49 to $10.70 per share.

How many ABCL shares does Michael R. Hayden indirectly hold after this transaction?

After the reported purchase, one indirect account holds 1,373,397 AbCellera (ABCL) Common Shares. A separate indirect position of 118,245 Common Shares is reported as held by his spouse.

Who has voting and investment power over the ABCL shares held through Genworks 2?

The AbCellera (ABCL) shares reported in the main transaction are held by Genworks 2 Consulting, Inc., and the reporting person’s spouse has sole voting and investment power over those shares.

Does Michael R. Hayden claim full beneficial ownership of these ABCL shares?

No. He disclaims beneficial ownership of the AbCellera (ABCL) shares held by Genworks 2, except to the extent of any indirect pecuniary interest he may have in them.

Were Michael R. Hayden’s ABCL trades made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not checked, indicating the reported AbCellera (ABCL) transactions are not affirmatively reported as made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 05:22 PM EDT Accepted by SEC EDGAR 08/24/2026 - 05:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hayden Michael R

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/24/2026		P	V	53,613	A	$10.64(1)	1,373,397	I(2)	See footnote
Common Shares								118,245	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.49 to $10.70. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

2. These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

Remarks:

	Tryn Stimart, attorney-in-fact	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)